Hikma announces exclusive agreement with Sciecure Pharma for niche injectable anti-viral medicine

London, 3 January 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement between its wholly-owned subsidiary Hikma Pharmaceuticals International Limited and Beijing Sciecure Pharmaceutical Co., Ltd (Sciecure), a leading Chinese company that researches, develops and manufactures high-quality pharmaceutical products for global markets.

Press Release Product 3 January 2019

Text 1

The agreement provides Hikma with exclusive rights to sell one of Sciecure’s niche injectable anti-viral medicines across the US for a minimum of eight years, with an option to extend this partnership for an additional two years. Sciecure expects to file this product for approval with the US Food and Drug Administration in early 2019.

“We are thrilled to partner with Sciecure, an innovative and vertically integrated company capable of producing high-quality products across the pharmaceutical spectrum from API to finished doses,” said Daniel Motto, Hikma’s Executive Vice President of Commercial and Business Development. “Our partnership with Sciecure is another example of how Hikma is continuing to expand its pipeline, targeting both niche products and high-volume opportunities, in order to offer a broad portfolio of high-quality medicines to US patients, physicians and hospitals.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.